Fortress Biotech, Inc. — fact timeline

Fortress Biotech, Inc. reported the first quarter ended March 31, 2026 results: net income $108.4 million, or $3.44 per common share (basic) and $2.82 per common share (diluted).

“Fortress’ consolidated net income attributable to common stockholders for the first quarter of 2026 was $108.4 million, or $3.44 per common share (basic) and $2.82 per common share (diluted)”

Fortress Biotech, Inc. reported financial results for the year ended December 31, 2025.

“On March 31, 2026, Fortress Biotech, Inc. issued a press release to provide a corporate update and to announce its financial results for the year ended December 31, 2025.”

Fortress Biotech, Inc. amended Second Amendment to Credit Agreement with Oaktree Fund Administration, LLC valued at Amended credit agreement dated July 25, 2024; $35.0 million initial borrowing, up to $15.0 million a (effective 2026-02-22).

“On February 22, 2026, the Company, as borrower, entered into the Second Amendment to Credit Agreement (the “ Second Amendment ”), which amends that certain Credit Agreement dated July 25, 2024 (the “ Original Agreement ”) with Oaktree Fund Administration, LLC, as the administrative agent (in such capacity, the “ Agent ”), and the lenders from time to time party thereto (as amended by that certain First Amendment to Credit Agreement dated December 12, 2025, collectively with the Original Agreement and the Second Amendment, the “ Loan Agreement ”).”

Fortress Biotech, Inc. entered into Priority Review Voucher Asset Purchase Agreement with Cyprium Therapeutics, Inc. valued at $205 million (effective 2026-02-22).

“On February 22, 2026, Cyprium Therapeutics, Inc. (“Cyprium”), a majority-owned subsidiary of Fortress Biotech, Inc. (the “ Company ”), entered into a definitive asset purchase agreement (the “ PRV APA ”) pursuant to which Cyprium agreed to sell a Rare Pediatric Disease Priority Review Voucher (“ PRV ”).”

Fortress Biotech, Inc. entered into First Amendment to Credit Agreement with Oaktree Fund Administration, LLC valued at $35.0 million initial borrowing; maturity extended to June 30, 2028; principal repayment schedule in (effective 2025-12-12).

“On December 12, 2025, Fortress Biotech, Inc. (the “ Company ”), as borrower, entered into the First Amendment to Credit Agreement (the “ Amendment ”), which amends that certain Credit Agreement dated July 25, 2024 (the “ Agreement ”) with Oaktree Fund Administration, LLC, as the administrative agent (in such capacity, the “ Agent ”), and the lenders from time to time party thereto.”

Fortress Biotech, Inc. issued up to 600,000 shares of warrant to the lenders (Oaktree Fund Administration, LLC and lenders from time to time party thereto) for purchase price of $2.62 per share.

“the Company granted warrants to the lenders to purchase up to 600,000 shares of the Company’s common stock, par value $0.001 per share (“ Common Stock ”), at a purchase price of $2.62 per share (the “ Warrants ”)”

Fortress Biotech, Inc. amended credit facility of up to $50.0 million with Oaktree Fund Administration, LLC maturing June 30, 2028.

“Under the terms of the Amendment, the Loan’s maturity date was extended from July 25, 2027 to June 30, 2028.”

Fortress Biotech, Inc. completed a disposition involving Sun Pharmaceutical Industries, Inc. for approximately $28.0 million in cash (closed 2025-05-30).

“as a subsidiary of Fortress (the “Subsidiary Sale”). In connection with the closing of the Merger and pursuant to the Merger Agreement, Fortress will receive approximately $28.0 million in cash and be eligible to receive up to an additional $4.8 million upon achievement of a regulatory milestone associated with the rights (“CVRs”) issued under a Contingent Value”

Lucy Lu was appointed as Chief Strategy Officer at Fortress Biotech, Inc..

“Dr. Lu’s decision to resign from the Board of Directors was made in connection with her accepting an offer to join the Company as Chief Strategy Officer effective April 21, 2025.”

Lucy Lu resigned as Director at Fortress Biotech, Inc..

“On April 15, 2025, Lucy Lu, M.D., notified Fortress Biotech, Inc. (the “ Company ”) of her resignation from the Board of Directors effective April 15, 2025.”

Fortress Biotech, Inc. reported financial results for first quarter ended March 31, 2024.

“Fortress Biotech, Inc. issued a press release to provide a corporate update and to announce its financial results for the three months ended March 31, 2024.”

Fortress Biotech, Inc. reported the full year ended December 31, 2023 results: revenue Record consolidated net revenue of $84.5 million.

“Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights Record consolidated net revenue of $84.5 million for full-year 2023”

Eric Rowinsky departed as Director at Fortress Biotech, Inc..

“Eric Rowinsky, M.D., a director currently serving on the board of directors of Fortress Biotech, Inc. (the “ Company ”), informed the Company that he does not intend to stand for re-election at the Company’s 2024 annual meeting of stockholders (the “ 2024 Annual Meeting ”) due to other professional commitments.”

Fortress Biotech, Inc. entered into Placement Agency Agreement with Roth Capital Partners, LLC (effective 2023-12-29).

“a Placement Agency Agreement, dated as of December 29, 2023, between the Company and Roth (the “ Placement Agency Agreement ”).”

Fortress Biotech, Inc. entered into Securities Purchase Agreement with the purchasers valued at approximately $11.0 million (effective 2023-11-10).

“a Securities Purchase Agreement (the “ Securities Purchase Agreement ”), dated November 10, 2023, between the Company and the purchasers party thereto.”

Fortress Biotech, Inc. reported third quarter ended September 30, 2023 results: revenue $34.8 million.

“in such filing. ​ --- EX-99.1 (EX-99.1) --- Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights ​ Total consolidated net revenue was $34.8 million in the third quarter of 2023, a 100% increase from total consolidated net revenue of $17.4 million in the second quarter of 2023 ​ Fortress is advancing several late-stage”

Fortress Biotech, Inc. entered into Placement Agent Agreement with Roth Capital Partners, LLC valued at 7.0% of the aggregate gross proceeds (effective 2023-11-10).

“a Placement Agent Agreement, dated as of November 10, 2023, between the Company and Roth (the “ Placement Agent Agreement ”).”

Fortress Biotech, Inc. entered into Securities Purchase Agreement with the purchasers party thereto valued at approximately $10.0 million (effective 2023-11-10).

“a Securities Purchase Agreement (the “ Securities Purchase Agreement ”), dated November 10, 2023, between the Company and the purchasers party thereto.”

Fortress Biotech, Inc.: The Company filed a Certificate of Amendment to effect a 1-for-15 reverse stock split of common stock, approved by stockholders and board, effective October 10, 2023 (effective 2023-10-10).

“On October 9, 2023, Fortress Biotech, Inc. (the “ Company ”) filed a Certificate of Amendment (the “ Amendment ”) to its Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of Delaware to effect a 1-for-15 reverse stock split (the “ Reverse Stock Split ”) of the Company’s shares of common stock, $0.001 par value (the “ Common Stock ”).”

Fortress Biotech, Inc. reported second quarter ended June 30, 2023 results: revenue $17.4 million.

“Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023”

Fortress Biotech, Inc.: Amendment to Article II, Section 7 of the bylaws changing the voting requirement for stockholder actions (effective 2023-08-10).

“the affirmative vote of a majority of the shares of stock present or represented at the meeting, by ballot, proxy or electronic ballot, unless a different or minimum vote is required by the Certificate of Incorporation, these Bylaws, the Delaware General Corporate Law, the rules or regulations of any stock exchange applicable to the corporation, or any law or regulation applicable to the corporation or its securities, in which case such different or minimum vote shall be the required vote on the matter.”

Fortress Biotech, Inc. shareholders approved Amendment to the ESPP to increase the shares of Common Stock available for issuance under the ESPP by 1,000,000 from 1,000,000 to 2,000,000 at the 2023-06-21 meeting.

“Proposal 4 The vote with respect to the approval of an amendment to Fortress’s ESPP was as follows: Total Votes For Total Votes Against Abstentions Broker Non-Votes 63,118,584 2,791,004 149,047 34,919,105”

Fortress Biotech, Inc. shareholders approved Amendment to the Incentive Plan to increase the shares of Common Stock available for issuance under the Incentive Plan by 7,000,000 shares from 16,000,000 to 23,000,000 and extend the term of the plan to December 31, 2033 at the 2023-06-21 meeting.

“Proposal 3 The vote with respect to the approval of an amendment to Fortress’s Incentive Plan was as follows: Total Votes For Total Votes Against Abstentions Broker Non-Votes 62,543,510 3,400,208 114,917 34,919,105”

Fortress Biotech, Inc. shareholders approved Ratification of the appointment of KPMG LLP as Fortress's independent registered public accounting firm for the year ending December 31, 2023 at the 2023-06-21 meeting.

“Proposal 2 The vote with respect to the ratification of KPMG LLP as Fortress’s independent registered accounting firm for the year ending December 31, 2023 was as follows: Total Votes For Total Votes Against Abstentions 100,561,358 349,645 66,737”

Fortress Biotech, Inc. shareholders approved Election of eight directors to hold office until the 2024 annual meeting of stockholders or until such director resigns or is removed from office at the 2023-06-21 meeting.

“Proposal 1 The votes with respect to the election of eight directors to hold office until the 2024 annual meeting of stockholders were as follows: Director Votes For Votes Withheld Broker Non-Votes Lindsay A. Rosenwald, M.D. ​ 65,231,237 ​ 827,398 ​ 34,919,105 Michael S. Weiss ​ 63,192,696 ​ 2,865,939 ​ 34,919,105 Eric R. Rowinsky, M.D. ​ 59,716,534 ​ 6,342,101 ​ 34,919,105 J. Jay Lobell ​ 63,930,573 ​ 2,128,062 ​ 34,919,105 Jimmie Harvey, Jr., M.D. ​ 65,276,580 ​ 782,055 ​ 34,919,105 Dov Klein, C.P.A. ​ 60,924,252 ​ 5,134,383 ​ 34,919,105 Malcolm Hoenlein ​ 60,908,825 ​ 5,149,810 ​ 34,919,105 Kevin L. Lorenz, J.D. ​ 60,998,382 ​ 5,060,253 ​ 34,919,105 Lucy Lu, M.D. ​ 64,968,753 ​ 1,089,882 ​ 34,919,105”

Fortress Biotech, Inc. amended Letter Agreement regarding Amended and Restated Warrants with Oaktree Fund Administration, LLC and certain affiliates valued at Lowered exercise price of Existing Warrants from $3.20 to $0.5424 per share; issued Amended and Rest (effective 2023-06-13).

“On June 13, 2023, the Company entered into a Letter Agreement (the “Letter Agreement”) by and among the Company, the Agent and the Lenders, pursuant to which the Company agreed to lower the exercise price of the Existing Warrants to $0.5424 per share and issue amended and restated warrants reflecting the new exercise price (the “Amended and Restated Warrants”), as consideration for the Agent and Lenders’ agreement to permit the Company and/or certain of its subsidiaries to take certain actions.”

Fortress Biotech, Inc. reported financial results for for the quarter ended March 31, 2023.

“On May 15, 2023, Fortress Biotech, Inc. issued a press release to announce financial results and recent corporate highlights for the quarter ended March 31, 2023.”

Fortress Biotech, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(ii)).

“May 2, 2023, in accordance with Nasdaq Listing Rule 5810(c)(3)(A)(ii), the Staff granted the Company a second 180-calendar day grace period to regain compliance with the Rule. The Company intends to closely monitor the closing bid price for its Common Stock and consider all available options to remedy the bid price deficiency. In the event the Company is not able to demonstrate compliance with the Rule by October 30, 2023, the Staff will provide written notification that the Company’s Common Stock is subject to delisting, which the Company may appeal. The Company’s appeal request would stay an”

Fortress Biotech, Inc. shareholders approved Approval of the issuance of the rights and Contingent Subsidiary Securities in order to satisfy the requirements of Nasdaq Listing Rule 5635(c) at the 2023-04-10 meeting.

“Total Votes For Total Votes Against Abstentions Broker Non-Votes 50,498,193 9,743,984 112,852 0”

Fortress Biotech, Inc. reported full-year ended December 31, 2022 results: revenue $75.7 million.

“We also generated record consolidated net revenues of $75.7 million”

Fortress Biotech, Inc. entered into Securities Purchase Agreement with several institutional and accredited investors (effective 2023-02-07).

“On February 7, 2023, Fortress Biotech, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Securities Purchase Agreement ”) with each of several institutional and accredited investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell an aggregate of 16,642,894 shares (the “ Shares ”) of common stock of the Company”

Lucy Lu, M.D. was elected as Director at Fortress Biotech, Inc..

“On December 14, 2022, the Board of Directors (the “Board”) of the “Company elected Lucy Lu, M.D. as a new member of the Board.”

Fortress Biotech, Inc. reported the first nine months of 2022 results: revenue $59.3 million.

“Net revenue for the nine months of 2022 increased 17.5% period-over-period to $59.3 million”

Fortress Biotech, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“October 31, 2022, Fortress Biotech, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the bid price of the Company’s common stock, par value $0.001 per share (the “Common Stock”), had closed below $1.00 per share for 30 consecutive business days and, as a result, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which sets forth the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq’s notice has no immediate effect on the listing of the C”

David Jin was appointed as Chief Financial Officer at Fortress Biotech, Inc..

“effective August 16, 2022, David Jin, 32, who has served as the Company’s Vice President of Corporate Development and the Interim Principal Executive Officer and Chief Operating Officer of the Company’s subsidiary Avenue Therapeutics, Inc. (“Avenue”), was appointed Chief Financial Officer.”

Robyn Hunter resigned as Chief Financial Officer at Fortress Biotech, Inc..

“On July 21, 2022, Robyn Hunter, the Chief Financial Officer of Fortress Biotech, Inc. (the “Company”), provided notice to the Company of her resignation. Ms. Hunter’s resignation will be effective August 16, 2022.”